Epimediphine, a novel alkaloid from Epimedium koreanum inhibits acetylcholinesterase

Natural Product Research

Volumn 27, Issue 12, 2013, Pages 1067-1074

  Zhang, Xiaodan ^a   Oh, Mihyue ^b   Kim, Seulgi ^a   Kim, Jimin ^a   Kim, Hyeyeon ^a   Kim, Sungun ^a   Houghton, Peter J ^c   Whang, Wankyunn ^a  

^a Chung Ang University   (South Korea)

^b Korea Food and Drug Administration   (South Korea)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; anticholinesterase activity; Epimediphine; Epimedium koreanum

Indexed keywords

ACETYLCHOLINESTERASE; ALKALOID; DEHYDROEVODIAMINE; EPIMEDIPHINE; PHYSOSTIGMINE; TACRINE; UNCLASSIFIED DRUG;

ARTICLE; BRAIN BLOOD FLOW; CHOLINESTERASE INHIBITION; EPIMEDIUM; EPIMEDIUM KOREANUM; GASTROINTESTINAL TOXICITY; HETERONUCLEAR MULTIPLE BOND CORRELATION; HETERONUCLEAR SINGLE QUANTUM COHERENCE; IC 50; LIVER TOXICITY; NONHUMAN;

ACETYLCHOLINESTERASE; ALKALOIDS; APORPHINES; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIMEDIUM; HUMANS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; PHYSOSTIGMINE; TACRINE;

EPIMEDIUM KOREANUM;

EID: 84879677127     PISSN: 14786419     EISSN: 14786427     Source Type: Journal    
DOI: 10.1080/14786419.2012.708660     Document Type: Article

References (19)

1. Guinaudeau, H., Leboeuf, M., & Cave, A. (1975). Aporphine alkaloids. Lloydia, 38, 275-338.
2. Heinze, M., Andreae, D., & Grohmann, R. (2002). Rivastigmin and impaired motor function. Pharmacopsychiatry, 35, 79-80.
3. Hsu, H.Y., Chen, Y.P., Shen, S.J., Hsu, C.S., Chen, C.C., & Chang, H.C. (1986). Oriental materia medica - A concise guide. Taipei, Taiwan: Orienal Healing Arts Instiute.
4. Huang, C.C., Liu, C.C., Chang, Y.C., Chen, C.Y., Wang, S.T., & Yeh, T.F. (1999). Neurologic complications in children with enterovirus 71 infection. New England Journal of Medicine, 341, 936-942.
5. Jiang, H., Luo, X., & Bai, D. (2003). Progress in clinical, pharmacological, chemical and structural biological studies of huperzine A: a drug of traditional chinese medicine origin for the treatment of Alzheimer's disease. Current Medicinal Chemistry, 10, 2231-2252.
6. Lu, S.H., Wu, J.W., Liu, H.L., Zhao, J.H., Liu, K.T., Chuang, C.K., & Ho, Y. (2011). The discovery of potential acetylcholinesterase inhibitors: a combination of pharmacophore modeling, virtual screening, and molecular docking studies. Journal ofBiomedical Science, 18, 8.
7. Ma, X., & Gang, D.R. (2008). In vitro production of huperzine A, a promising drug candidate for Alzheimer's disease. Phytochemistry, 69, 2022-2028.
8. Ma, H., He, X., Yang, Y., Li, M., Hao, D., & Jia, Z. (2011). The genus Epimedium: an ethnopharmacological and phytochemical review. Journal ofEthnopharmacology, 134, 519-541.
9. Melzer, D. (1998). New drug treatment for Alzheimer's disease: lessons for healthcare policy. British Medical Journal, 316, 762-764.
10. Mitsui, T., & Fujimura, Y. (1975). Examination of concentration of dragendroffs reagent preparaton. Japanese Journal of Toxicology and Enviromental Health, 21, 183-187.
11. Oh, M.H., Houghton, P.J., Whang, W.K., & Cho, J.H. (2004). Screening of Korean herbal medicines used to improve cognitive function for anti-cholinesterase activity. Phytomedicine, 11, 544-548.
12. Park, C.H., Kim, S.H., Choi, W., Lee, Y.J., Kim, J.S., & Suh, Y.H. (1996). Novel anticholinesterase and antiamnesic activities of dehydroevodiamine, a constituent of Evodia rutaecarpa. Planta Medica, 62, 405-409.
13. Paton, C., & Branford, D.B. (1997). Advances in the Alzheimer's disease. Pharmaceutical Journal, 259, 693-696.
14. Perry, N.S., Houghton, P.J., Theobald, A., Jenner, P., & Perry, E.K. (2000). In-vitro inhibition of human erythrocyte acetylcholinesterase by Salvia lavandulaefolia essential oil and constituent terpenes. Journal of Pharmacy and Pharmacology, 52, 895-902.
15. Schiff, P.L. (1996). In S.W. Pelletier (Ed.), Alkanoid: Chemical and biological perspectives (1st ed.). Oxford, UK: Pergamon.
16. Schulz, V. (2003). Ginkgo extract or cholinesterase inhibitors in patients with dementia: what clinical trials and guidelines fail to consider. Phytomedicine, 10, 74-79.
17. Small, G.W., Rabins, P.V., Barry, P.P., Buckholtz, N.S., Dekosky, S.T., Ferris, S.H., & Larry, E. (1997). Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. Journal of the American Medical Association, 278, 1363-1371.
18. Tomita, M., & Nakano, T. (1957). Studies on the alkaloids of Rutaceous plants. I. Alkaloids of Phellodendron amurense Rupr. (1). Pharmaceutical Bulletin, 5, 10-12.
19. Watkins, P.B., Zimmerman, H.J., Knapp, M.J., Gracon, S.I., & Lewis, K.W. (1994). Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. Journal ofthe American Medical Association, 271, 992-998.